Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
histamine human immunoglobulin + loratadine
- Development stage
- Preclinical
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral, Intravenous
01
Overview
A combination drug consisting of **histamine human immunoglobulin** and **loratadine**. Loratadine is a second-generation antihistamine that acts as an inverse agonist at the histamine H1 receptor, blocking the effects of endogenous histamine and reducing symptoms of allergic rhinitis, urticaria, and other allergic dermatological conditions[3]. Loratadine additionally inhibits histamine release from human basophils[1]. Histamine human immunoglobulin is an immunoglobulin-based preparation that contains human antibodies directed at histamine; such preparations are generally used in immunomodulation and may modulate allergic or immune responses.
02
Targets
HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on histamine human immunoglobulin + loratadine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on histamine human immunoglobulin + loratadine.